open access

Vol 5, No 1 (2019)
Przypadki kliniczne
Published online: 2019-04-04
Get Citation

Differential diagnosis of inflammatory myopathies, Becker muscular dystrophy (BMD) in a 10-year-old boy

Dorota Turowska-Heydel, Zbigniew Żuber
DOI: 10.5603/FR.2019.0006
·
Forum Reumatologiczne 2019;5(1):43-46.

open access

Vol 5, No 1 (2019)
Przypadki kliniczne
Published online: 2019-04-04

Abstract

The article presents the case of a 10-year-old boy referred for rheumatic diagnosis with suspected inflammation of the muscles without the presence of skin lesions in which Becker muscular dystrophy (BMD) was diagnosed. In cases of isolated myopathy without skin lesions, it is necessary to exclude the neurogenic origin of muscle damage, muscular dystrophies and myasthenic disorders, additionally, viral, bacterial, parasitic infectious myopathy should be considered as a result of hormonal disturbances, drug poisoning and metabolic and electrolyte disorders. Becker muscular dystrophy is a genetically conditioned disease that causes progressive and irreversible muscular atrophy, and is inherited in a recessive manner in gender-related intercourse. The incidence is around 1.5–6/100,000 births of boys. Becker dystrophy is a milder form of the Duchenne dystrophy type (DMD). The first symptoms occur at the age of 6–12 years. They include duck feet, problems with running and climbing stairs. The disease is progressive, initially affects the skeletal muscles, then also the myocardium leading to cardiomyopathy. Loss of ability to move independently occurs later, only after the age of 16. The average survival period is 45 years.

Forum Reumatol. 2019, tom 5, nr 1: 43–46

Abstract

The article presents the case of a 10-year-old boy referred for rheumatic diagnosis with suspected inflammation of the muscles without the presence of skin lesions in which Becker muscular dystrophy (BMD) was diagnosed. In cases of isolated myopathy without skin lesions, it is necessary to exclude the neurogenic origin of muscle damage, muscular dystrophies and myasthenic disorders, additionally, viral, bacterial, parasitic infectious myopathy should be considered as a result of hormonal disturbances, drug poisoning and metabolic and electrolyte disorders. Becker muscular dystrophy is a genetically conditioned disease that causes progressive and irreversible muscular atrophy, and is inherited in a recessive manner in gender-related intercourse. The incidence is around 1.5–6/100,000 births of boys. Becker dystrophy is a milder form of the Duchenne dystrophy type (DMD). The first symptoms occur at the age of 6–12 years. They include duck feet, problems with running and climbing stairs. The disease is progressive, initially affects the skeletal muscles, then also the myocardium leading to cardiomyopathy. Loss of ability to move independently occurs later, only after the age of 16. The average survival period is 45 years.

Forum Reumatol. 2019, tom 5, nr 1: 43–46

Get Citation

Keywords

myositis; muscular dystrophy; molecular diagnostics

About this article
Title

Differential diagnosis of inflammatory myopathies, Becker muscular dystrophy (BMD) in a 10-year-old boy

Journal

Forum Reumatologiczne

Issue

Vol 5, No 1 (2019)

Pages

43-46

Published online

2019-04-04

DOI

10.5603/FR.2019.0006

Bibliographic record

Forum Reumatologiczne 2019;5(1):43-46.

Keywords

myositis
muscular dystrophy
molecular diagnostics

Authors

Dorota Turowska-Heydel
Zbigniew Żuber

References (8)
  1. Kissel JT, Mendell JR. Muscular dystrophy: historical overview and classification in the genetic era. Semin Neurol. 1999; 19(1): 5–7.
  2. Hausmanowi-Petrusewicz I. Choroby nerwowo-mięśniowe. Czelej, Lublin 2005: 167–178.
  3. Szmidt-Sałkowska E. Dorobek M. Nowe poglądy na patogenezę dystrofii mięśniowych postępujących (DMP) Polski przegląd Neurologiczny. 2006; 2: 117–124.
  4. Koening M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker Muscular Dystrophy: correlation of severity with type of deletion . Am.J.Hum.Genet. 1989; 45: 498–506.
  5. Behrman RE, Kliegman RM, Nelson WE, Vaughan VC. Podręcznik pediatrii . PWN, Warszawa 1996.
  6. Passamano I, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myologica. 2012; XXXI: 121–125.
  7. Andrews JG, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther. 2018; 9: 53–63.
  8. Beenakker EAC, Fock JM, Van Tol MJ, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol. 2005; 62(1): 128–132.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl